From GlobeNewswire: 2025-04-16 01:15:00

Basilea Pharmaceutica Ltd presented data on their novel antifungal fosmanogepix at the ESCMID Global 2025 meeting in Vienna. Over 250 patients with severe fungal infections received fosmanogepix via expanded access, showing favorable response rates of 70% or higher in patients with invasive fusariosis or mucormycosis. The drug also demonstrated activity against various yeast and mold species. Isavuconazole (Cresemba) and ceftobiprole (Zevtera) were also discussed at the conference, highlighting their efficacy in treating different fungal infections. Fosmanogepix has received Fast Track and Orphan Drug designations from the FDA for multiple indications, showing promise as a life-saving treatment option. Basilea, a biopharmaceutical company, has successfully launched Zevtera, an advanced generation cephalosporin antibiotic, for the treatment of bacterial infections. Zevtera is approved in Europe and beyond for adult patients with hospital-acquired bacterial pneumonia and community-acquired bacterial pneumonia. In the United States, Zevtera is indicated for Staphylococcus aureus bloodstream infections and acute bacterial skin infections in adults, as well as community-acquired bacterial pneumonia in both adults and pediatric patients. Basilea is dedicated to developing innovative drugs to address severe bacterial and fungal infections.



Read more at GlobeNewswire: Basilea reports presentation of new data for fosmanogepix,